



Recent Advances in Green Chemistry Approaches for the Sustainable Synthesis of Pharmaceutical Intermediates

Harishchandra Nareti¹, Aayushi Lingayya¹, Satish Kumar Patel¹, Ajita Khichariya¹, Vinay Sagar Verma^{1*}

¹Kamla Institute of Pharmaceutical Sciences, Shri Shankaracharya Professional University, Junwani, Bhilai, Durg, Chhattisgarh, India. PIN-490020.

*Corresponding Author E-mail: vinaysagrverma@gmail.com

Abstract:

The pharmaceutical industry stands at a critical juncture regarding environmental sustainability. Conventional synthetic routes for active pharmaceutical ingredients (APIs) and intermediates generate substantial waste, averaging 35–503 kg per kilogram of API, depending on molecular complexity, with cumulative annual environmental and economic costs exceeding \$20 billion globally. This unsustainable trajectory, combined with the strengthening of regulatory frameworks and corporate environmental commitments, has catalysed a fundamental transformation in the philosophy of pharmaceutical synthesis. Green chemistry, defined as the design of chemical products and processes that reduce or eliminate the generation of hazardous substances, has evolved from an academic aspiration into an essential industrial competency. This comprehensive review synthesises recent advances (2022–2025) across seven primary technological paradigms: biocatalysis and enzymatic synthesis, continuous-flow chemistry, innovative solvent systems (supercritical fluids and ionic liquids), mechanochemistry, photoredox catalysis, electrochemical synthesis, and renewable feedstock integration. Through systematic analysis of regulatory drivers, mechanistic innovations, industrial case studies, and quantitative performance metrics (atom economy, E-factor, process mass intensity), this review demonstrates that pharmaceutical intermediates synthesised via green methodologies now routinely achieve 50–90% waste reduction, superior stereochemical control, and improved economic viability compared to legacy synthetic routes. Integration of artificial intelligence, digital process modelling, and hybrid catalytic platforms represents the frontier of this transformation, promising unprecedented efficiency gains and environmental stewardship for pharmaceutical manufacturing in the coming decade.

Keywords: Pharmaceutical Industry; Environmental Commitments; Photoredox; Green Chemistry

Received: July 10, 2026

Revised: Aug. 19, 2026

Accepted: Sep. 28, 2026

Published: Oct. 28, 2026

DOI: <https://doi.org/10.64062/IJPCAT.Vol2.Issue5.2>

<https://ijpcat.com/index.php/1/issue/archive>

This is an Open Access article distributed under the terms of the Creative Commons Attribution (CC BY NC), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers. (<https://creativecommons.org/licenses/by-nc/4.0/>)

1. Introduction and Strategic Context

1.1 The Pharmaceutical Waste Crisis

The synthesis of pharmaceutical compounds represents one of the most chemically intensive industries globally, with profound environmental consequences that have only recently gained proportionate regulatory and commercial attention. The scope of the challenge is staggering: global API manufacturing generates approximately 10 billion kilograms of waste annually, with inadequate municipal or industrial infrastructure for treatment in many regions, particularly in developing nations where contract manufacturing is concentrated^{1,2}. This waste encompasses:

- Organic solvents: Often the most significant mass contributor (50–80% of batch process mass), volatile organic compounds pose atmospheric, aquatic, and occupational hazards
- Stoichiometric reagents: Excess metal salts, bases, and oxidising agents that become waste after single-use
- Auxiliary materials: Protecting groups, linkers, and resolving agents consumed in asymmetric synthesis or purification
- Aqueous waste streams: Contaminated with residual organics, metals, and salts requiring energy-intensive treatment

This waste generation is not merely an environmental externality—it incurs substantial direct costs. Hazardous waste treatment and disposal costs an average of \$2 per kilogram, totalling \$20 billion annually for the global pharmaceutical industry. For a generic manufacturer operating on thin margins (typically 5–15% gross profit), waste reduction directly enhances financial viability and competitive positioning.

1.2 The Regulatory and Market Evolution

The trajectory toward mandatory adoption of green chemistry has accelerated dramatically. The U.S. Food and Drug Administration's emphasis on Quality by Design (QbD) and Process Analytical Technology (PAT), codified in ICH Q8, indirectly but powerfully incentivises process design by discouraging late-stage manufacturing changes. The European Medicines Agency's Environmental Risk Assessment (ERA) guidance, effective September 2024, establishes formal requirements for environmental lifecycle analysis of pharmaceuticals, elevating green chemistry from aspirational to mandatory consideration^{3,4}. Regulatory agencies have recognised processes for establishing superior waste profiles, cleaner impurity patterns, and robust control strategies as presenting lower overall risk, potentially accelerating the approval timeline and providing a strategic advantage in generic and novel drug development. The Chemical Society's Green Chemistry Institute Pharmaceutical Roundtable (GCIPR), composed of senior scientists from 20+ major pharmaceutical companies, institutionalised the adoption of green metrics (particularly Process Mass Intensification) as a standard for evaluation, signalling industry-wide consensus that sustainability is inseparable from good manufacturing practice^{2,5}.

1.3 Scope and Organisation Organization

This review focuses on the synthesis of pharmaceutical intermediates, defined as molecular scaffolds that are one to three synthetic steps removed from the final active pharmaceutical ingredients. These intermediates represent a critical bottleneck in pharmaceutical supply chains because they must meet stringent requirements for purity, typically exceeding 95 percent, maintain precise stereochemical control across multiple chiral centers, and remain scalable to multi-ton production ⁶. Traditionally, achieving these standards has relied on labor-intensive separation and purification strategies, leading to resource- and energy-intensive manufacturing processes. In contrast, many emerging synthetic technologies deliver superior performance across these dimensions by streamlining transformations, minimizing byproduct formation, and reducing the need for extensive downstream processing. By examining these technologies from both mechanistic and environmental perspectives, this review evaluates their current state of development and outlines their projected maturation trajectory through 2030 ⁷. Figure 1




Figure 1. Pharmaceutical Intermediate Synthesis: From Conventional to Green Chemistry Paradigms

2. Biocatalysis and Enzymatic Synthesis: Industrial Maturation

2.1 Paradigm Shift from Stoichiometric to Catalytic Processes

The fundamental breakthrough underpinning biocatalytic pharmaceutical synthesis is conceptual: replacement of stoichiometric reagents (consumed 1:1 with substrate) with catalytic enzymes (recycled through cofactor regeneration or direct turnover). catalysts that catalyse 1,000 turnovers per molecule, eliminating catalysis-related waste inherent in stoichiometric methods. While enzyme catalysis has ancient roots in fermentation, the past decade has witnessed unprecedented acceleration in enzyme discovery, engineering, and scalable production, driven by the convergence of genomic sequencing, high-throughput screening automation, directed evolution algorithms, and computational tools for protein engineering^{8,9}. This shift toward catalytic, rather than stoichiometric, chemistry is not confined to enzymology: parallel advances in the design and characterisation of novel organometallic complexes and in advanced catalytic materials for hydrogen-related processes illustrate the same underlying principle across chemocatalytic and biocatalytic domains alike.

2.2 Engineered Amine Transaminases: The Sitagliptin Paradigm

The synthesis of sitagliptin (Januvia®), a diabetes therapeutic, exemplifies the transformative potential of this approach. Merck and Codexis jointly developed an engineered amine transaminase that catalyses asymmetric transamination of a ketone intermediate, producing chiral amine in a single step. This landmark 2010 Presidential Green Chemistry Challenge Award-winning process demonstrates quantifiable benefits:

Parameter	Legacy Chemical Route	Biocatalytic Route
Yield (overall)	~80%	~92% (10-13% improvement)
Waste byproducts (kg per kg API)	Substantial (rhodium catalyst, stoichiometric reagents)	Minimal (enzyme biodegradable, cofactor recycled)
Atom economy (key step)	<40% (stoichiometric ruthenium catalyst)	>95% (enzymatic transamination)
E-factor	>50	~5.8–8.0 ,
Waste reduction vs. baseline	—	19% improvement documented
Energy intensity	Moderate (cooling required for precision)	Low (room temperature, aqueous)

The Merck-Codexis collaboration exemplifies the engineering complexity and optimisation. No natural ATA possessed the requisite activity optimisation for the sitagliptin substrate. Codexis' proprietary directed evolution platform subjected candidate enzymes to iterative cycles of random mutagenesis, high-throughput screening (testing millions of variants), and rational design refinement. The resulting engineered enzyme achieved a ~1,000-fold increase in activity, enabling practical multi-kilogram synthesis at a substrate concentration of 75 g/L with >99% enantiomeric excess^{10,11}.

2.3 Expanded Biocatalytic Arsenal: Recent Advances

The success catalysed the systematic exploration of enzyme catalysis across the space of catalytic intermediate synthesis. Representative recent advances (2023–2025) include:

2.3.1 Asymmetric Amine Synthesis

Engineered reductive aminating imine reductases (IRed) now enable complex chiral amine production at multi-kilogram scale. A paradigmatic example is the synthesis of a key tofacitinib intermediate (a JAK inhibitor for rheumatoid arthritis), IRED-catalysed reduction of an imine precursor, yielding 74% isolated yield, >99.9% enantiomeric excess, and 98:2 diastereomeric ratio. Contiguous stereogenic centre formation via engineered IReds represents a transformative capability, enabling synthetic routes that are inaccessible via traditional chiral chemistry^{10,11}.

2.3.2 Amino Acid Derivatisation Derivatization

Industrial production of β -alanine, a commodity intermediate for vitamin B5 synthesis that requires multi-thousand-ton annual production, has undergone a revolutionary redesign. Traditional chemical synthesis proceeds via the hydration of acrylic acid over metal catalysts or the reduction of nitriles, both of which generate substantial waste. Engineered aspartame variants, developed through computational design and directed catalysis, now catalyse direct ammonia addition to acrylic acid to form L- β -catalyse. While industrial deployment remains pending (yield and kinetic metrics optimisation), the proof-of-concept demonstrates conceptual optimisation, replacing stoichiometric synthetic routes with biological equivalents^{9,12}.

2.3.3 Alcohol Oxidation via Engineered Alcohol Dehydrogenases

A gamma-secretase inhibitor intermediate was synthesised via the asymmetric reduction of a ketone to a chiral secondary alcohol. Researchers screened 190 commercially available alcohol dehydrogenases (ADHs) and identified a c-LEcta ADH variant that provides superior selectivity and high specific activity. Incorporation into a multi-kilogram process exemplifies Enz discovery's practical maturation rather than de novo enzyme engineering. High-throughput enzyme screening now identifies suitable biocatalysts from existing panels within project timelines^{9,10}.

2.3.4 Complex Cascade Reactions and Multi-Enzyme Systems

The frontier of biocatalysis involves multi-enzyme cascades performing sequential transformations in single reactors without intermediate isolation. A landmark example: synthesis of pseudo uridine (Ψ), a modified nucleoside stabilising effects on synthetic mRNAs, via a cascade of three stabilising enzymes: uridine phosphorylase, phosphopentamutase, and nucleoside C-glycosidase that isomerises uridine to Ψ and its 5'-monophosphate. Such cascading eliminates separation waste and enables thermodynamic driving force from sequential exergonic reactions^{13,14}.

2.4 Cofactor Regeneration and Process Intensification

A persistent challenge in enzymatic synthesis is the use of expensive or toxic cofactors (NAD⁺, ATP, SAM). Modern biocatalysis addresses this through^{9,12}:

1. Coupled enzyme systems: Secondary enzymes regenerate cofactors in situ; exemplified by amine transaminase coupled with formate dehydrogenase for cofactor (pyridoxal phosphate).
2. Immobilised enzyme systems: Cofactors covalently attached to Immobilised solid supports, enabling multiple reuse cycles
3. Chemical regeneration systems: Electrochemical or chemical methods (hydrazine, formic acid) regenerate cofactors at cost-competitive levels
4. Engineered self-sufficient enzymes: Protein engineering eliminates cofactor requirement for select transformations

2.5 Regulatory Pathway and Scale-Up Considerations

Biocatalytic processes must navigate regulatory pathways identical to those for chemical routes, CMC (Chemistry, Manufacturing, and Controls) documentation, stability data, and impurity qualification, while also addressing the added complexities of enzyme source disclosure and manufacturability demonstration. The FDA and EMA have established no specific barriers to biocatalytic processes; indeed, the agencies tacitly endorse them through alignment with the QbD framework and recognition of their environmental impacts. Commercial challenges centre on:

- Enzyme supply security: Dependence on a single vendor or fermentation facility creates supply chain vulnerability
- Comparability assessments: Enzyme batches exhibit natural variation; process robustness requires demonstration across vendor lots
- Cold chain requirements: Most enzymes require storage at 2–8°C, complicating immobilisation.
- Immobilisation economics: Enzyme carrier costs must be justified by the reuse cycles

Despite these logistical complexities, the competitive advantages of superior selectivity, waste reduction, and regulatory favourability have driven adoption. Codexis and Merck continue expanding their partnership, with over 15 pharmaceutical programs now employing engineered biocatalysts at commercial scale, validating the paradigm's maturation^{11,15}.




Figure 2. Biocatalysis in Pharmaceutical Intermediate Synthesis: Enzyme Classes and Industrial Case Studies

3. Continuous Flow Chemistry: From Academia to Manufacturing Reality

3.1 Conceptual Foundation and Processing Paradigm

Continuous flow chemistry represents a fundamental redesign of chemical reactor architecture: replacing batch reactors (chemicals mixed, reacted for a fixed time, products removed) with plug-flow tubular reactors where reactants enter continuously, react during transit, and products exit continuously. This ostensibly simple architectural shift enables transformative process intensification:

Parameter	Batch Reactor	Continuous Flow Reactor
Residence time	Fixed (hours)	Tunable (seconds to minutes)

Temperature control	Bulk heating/cooling; gradients are common	Precise local temperature; radial uniformity
Pressure profile	Isochoric (fixed volume)	Adjustable via pump pressure
Mixing efficiency	Impeller-dependent; dead zones possible	Forced convection; near-plug flow
Thermal runaway risk	Significant, exothermic reactions are dangerous at scale	Minimal; small reactor volume dissipates heat rapidly
Reproducibility	Sensitive to operating parameters	Highly reproducible; identical residence time distribution

The reactor volume constraint in continuous flow systems (typically 0.5–10 mL for pilot-scale microreactors, 100–500 mL for production-scale) creates what chemists term "intrinsic safety" – hazardous chemistries (azide couplings, diazo compound generation, explosion cyclization's n's) become feasible at industrial scale precisely because the small inventory of reactive material cannot sustain autocatalytic runaway reactions^{16,17}.

3.2 Multi-step Continuous Synthesis: From Proof-of-Concept to Industrial Implementation

3.2.1 Aliskiren Hemi fumarate: Novartis–MIT Paradigm

One of the most influential demonstrations of multi-step continuous manufacturing is the end-to-end synthesis of aliskiren hemifumarate, marketed as Tekturna®, developed at the Novartis–MIT Centre for Continuous Manufacturing. In this process, four individual chemical transformations are seamlessly integrated into a single continuous stream without isolation of intermediates. The entire synthesis is completed within approximately one hour, compared with nearly forty-eight hours required for conventional batch processing. The process is deliberately designed to minimise solvent use, operating with concentrated reaction streams and avoiding unnecessary dilution. As a result, the cumulative yield is roughly double that of the batch route, reflecting superior mass balance and reduced material loss. From a safety standpoint, continuous operation eliminates manual handling of hazardous intermediates, with their generation and consumption tightly controlled by stoichiometric pump rates. Most steps operate at ambient temperature and pressure, with heating applied only where thermodynamically essential. Product recovery is achieved directly by crystallisation from the flowing stream, removing the need for energy-intensive solvent evaporation. Beyond laboratory success, the platform demonstrates straightforward scalability, as throughput can be increased by scaling up parallel reactors, supporting multi-ton-per-hour production and establishing continuous flow as a viable commercial manufacturing strategy^{17,18}.

3.2.2 Tamoxifen: Organometallic Coupling Exemplar

Tamoxifen, a widely used estrogen receptor antagonist in breast cancer therapy, is traditionally synthesised through a multi-step batch route involving hazardous organometallic reactions

such as Wittig and Grignard couplings. These transformations pose significant thermal runaway risks when scaled. A landmark study by Steven V. Ley and collaborators demonstrated that all four key steps could be integrated into a continuous flow process. Precise temperature control within flow reactors enabled safe management of highly exothermic organometallic reactions, even at scale. The constant approach delivered improved selectivity, simplified downstream processing through direct crystallisation or liquid–liquid extraction from the reactor effluent, and substantially reduced operator exposure to reactive intermediates. This work provided a clear example of how continuous flow can mitigate inherent safety risks associated with classical batch organometallic chemistry ^{19,20}.

3.2.3 Pharmaceutical Intermediate Production: Scalability Demonstration

Transitioning continuous flow chemistry from milligram-scale academic demonstrations to kilogram and multi-kilogram pharmaceutical production requires robust engineering and validation, but recent industrial examples show that this transition is achievable. In 2024, Boehringer Ingelheim and Pharma Block received U.S. EPA Green Chemistry Challenge Awards for their flow-based manufacturing processes. Boehringer Ingelheim developed a three-step asymmetric continuous synthesis of a Spiro ketone intermediate (CD 7659), increasing overall yield from 10 per cent to 47 per cent, while reducing organic solvent use by 99 per cent and water consumption by 76 per cent, with production demonstrated at multi-kilogram scale. Pharma Block implemented micro-packed-bed flow-reactor technology for the synthesis of tert-butyl 3-oxoazetidine-1-carboxylate, integrating oxidation and reductive amination steps in sequence. This approach reduced process mass intensity by more than 50 per cent and delivered superior equipment volume efficiency compared with batch processing ^{17,20}.

3.3 Advanced Flow Technologies

Continuous flow platforms have expanded well beyond conventional thermal chemistry. Photo flow reactors integrate light sources such as LEDs or fibre optics directly into reactor tubing, enabling highly controlled photocatalytic and photoredox reactions. Residence times on the order of seconds to minutes are matched precisely to reaction kinetics, avoiding over-irradiation and suppressing byproduct formation that commonly plagues batch photochemistry. These systems have been applied to trifluoromethylation, C–H functionalization, and heterocycle synthesis at scales relevant to pharmaceutical manufacturing.

Electro flow reactors incorporate electrochemical transformations into continuous systems, allowing fine control of redox potential through reference electrodes and potentiation or galvanostatic operation. This enables oxidative and reductive reactions without stoichiometric chemical reagents, with reactive intermediates generated in situ and consumed immediately downstream. Continuous electrochemical synthesis of nitrogen-, sulphur-, and oxygen-containing heterocycles has been demonstrated at kilogram-scale throughput ^{21,22}.

Computational tools are also playing an increasingly important role. Coupling computational fluid dynamics with design-of-experiments strategies enables the prediction of mixing behaviour, residence time distributions, and reaction kinetics in flow reactors. A representative

example is the optimisation of the first step in GlaxoSmithKline's cabotegravir synthesis, where CFD models predicted optimal operating conditions with greater than 95 per cent accuracy, significantly reducing experimental development time^{17,23}.

Statistically driven design-of-experiments and custom design approaches are similarly being applied outside the flow reactor itself, for instance in the optimisation of oxidative derivatisation reactions used to convert polyethylene glycol into biocompatible polyethylene carboxylate scaffolds for bioactive conjugation, underscoring the broader value of formal statistical optimisation for reducing experimental burden across green synthetic and polymer-functionalisation chemistry alike^{24,25}.

Self-optimising flow platforms that pair reinforcement learning with in-line analytics are a further extension of this computational trend. Deep reinforcement learning agents have been used to autonomously identify optimal temperature, stoichiometry, and residence time for imine-forming reactions relevant to pharmaceutical intermediates, reducing the experimental burden required to reach optimal operating conditions relative to conventional design-of-experiments approaches²⁶.

3.4 Challenges and Regulatory Considerations

Despite clear technical and sustainability advantages, adoption of continuous flow manufacturing faces persistent challenges, particularly in the generic pharmaceutical sector, where batch processes are deeply entrenched. High initial capital investment, often in the range of several hundred thousand to a few million dollars, can deter adoption without guaranteed long-term production volumes. Regulatory comparability requirements require demonstrating equivalence between batch and continuous processes, and first-cycle approvals for fully continuous routes remain relatively uncommon. Scale-up is not always straightforward, as optimal parameters can shift with reactor size, requiring re-optimisation during technology transfer. Continuous systems may also be less tolerant of variability in raw material quality, placing greater emphasis on supplier qualification and control.

Nevertheless, regulatory momentum is clearly shifting. The U.S. Food and Drug Administration has explicitly encouraged continuous manufacturing, with guidance and prioritisation reflected in IND and ANDA submissions. The first approval of a continuously manufactured commercial generic by Janssen Pharmaceuticals in 2023 marked a critical milestone, signalling growing regulatory confidence and setting the stage for broader industrial adoption^{19,27}.

Harmonisation at the guideline level has also advanced: the ICH Q13 guideline on continuous manufacturing of drug substances and drug products, finalised in 2022 and brought into effect by regulators in 2023, provides a common framework of scientific and regulatory expectations for developing, implementing, and managing continuous processes across regions, further de-risking industry investment in flow-based manufacturing²⁸.




Figure 3. Continuous Flow Chemistry for Sustainable Pharmaceutical Manufacturing

4. Alternative Solvents and Solvent-Free Synthesis

4.1 The Solvent Crisis in Pharmaceutical Synthesis

Organic solvents dominate the material footprint of pharmaceutical synthesis, accounting for 50–80 per cent of the total batch mass and nearly three-quarters of the overall environmental impact. This burden arises from energy-intensive solvent recovery, waste treatment, and atmospheric emissions. Widely used solvents such as toluene, tetrahydrofuran, and dichloromethane raise concerns related to toxicity, volatility, and environmental persistence. At an industry scale, the impact is enormous. A single API produced at 1,000 tons per year using solvent-intensive routes can generate hundreds of thousands of tons of waste solvent annually, highlighting the urgent need for alternative solvent strategies ^{2,29}.

4.2 Supercritical Carbon Dioxide: Rational Design for Green Chemistry

Supercritical carbon dioxide, achieved above 31.1°C and 72.8, combines gas-like diffusivity with liquid-like solvation, making it an attractive green solvent. It is non-toxic, non-flammable, and mainly sourced from recycled industrial CO₂ streams, enabling closed-loop use. Its solvent power can be tuned simply by adjusting pressure, allowing selective solubilization, while its low viscosity enhances mass transfer and reaction rates. Product isolation is straightforward, as depressurisation causes CO₂ to evaporate, often leaving crystalline products without significant thermal input³⁰.

In practice, scCO₂ has shown clear advantages in several reaction classes. Hydrogenation and hydroformylation benefit from the unusually high solubility of hydrogen in scCO₂, leading to dramatic rate enhancements compared with conventional solvents. Oxidation reactions, including benzyl alcohol oxidation and peroxide generation, exhibit improved selectivity and controllability through pressure modulation. Supercritical CO₂ has also been used for the polymerisation of lactones and cyclic esters, producing biodegradable polymer intermediates with controlled molecular weight distributions³⁰.

Despite these strengths, widespread adoption remains limited. The need for high-pressure reactors and associated safety systems requires significant capital investment, while compressing CO₂ to supercritical conditions is energy-intensive unless renewable electricity is used. Closed-loop CO₂ recovery and purification add further operational complexity. As a result, scCO₂ is currently more common in extraction and polymer processing than in routine pharmaceutical synthesis, although advances in reactor design and membrane-based CO₂ recovery are steadily improving feasibility³⁰.

4.3 Ionic Liquids: Liquid Solvents with Near-Zero Vapour Pressure

Ionic liquids represent a fundamentally different solvent class. These salts remain liquid below 100°C and exhibit negligible vapour pressure, eliminating solvent loss through evaporation. By selecting appropriate cation–anion combinations, properties such as polarity, viscosity, and thermal stability can be finely tuned. Many ionic liquids are stable above 300°C and can solubilise both polar and nonpolar compounds. Significantly, new generations of ionic liquids derived from renewable feedstocks, including amino acids and biomass components, are improving biodegradability profiles.^{31,32}

A closely related class, deep eutectic solvents (DES), is formed by simply combining a hydrogen-bond donor and acceptor, such as choline chloride with urea or a carboxylic acid, without further synthesis or purification. Beyond serving as reaction media, DES components can act directly as catalysts through hydrogen-bond activation, and have been applied to condensation, nucleophilic addition, and multicomponent reactions used in the construction of active pharmaceutical ingredients and their precursors, offering a low-cost, biodegradable complement to conventional ionic liquids³³.

In pharmaceutical synthesis, ionic liquids have enabled efficient Suzuki couplings with enhanced catalyst recycling, improved selectivity in Friedel–Crafts acylation, and robust performance in enzyme-catalysed reactions over many cycles. Olefination reactions such as

the Horner–Wadsworth–Emmons transformation have also been demonstrated with extensive solvent and catalyst reuse, sometimes across more than one hundred consecutive batches.

Hybrid systems combining ionic liquids with supercritical CO₂ are an emerging innovation. In these setups, the ionic liquid serves as the reaction medium, retaining catalysts or enzymes, while scCO₂ functions as a benign extraction phase to remove products. Both components are recyclable, enabling high atom economy and essentially eliminating solvent waste ^{30,32}.

4.4 Water as a Green Solvent: Aqueous and Micellar Systems

Water is the most sustainable solvent available, being abundant, non-toxic, inexpensive, and recyclable. Historically, its use in organic synthesis has been limited by the poor solubility of hydrophobic intermediates. Modern strategies, however, have overcome these limitations through improved catalyst design and micellar chemistry.

A landmark example is the aqueous redesign of the synthesis of sertraline hydrochloride by **Merck & Co.** In the original process, large volumes of toluene, hexane, and THF were used, along with titanium tetrachloride. The revised aqueous route replaces organic solvents with water, eliminates the use of TiCl₄ in favour of a water-compatible catalyst, and eliminates the need for palladium on carbon. The outcome is comparable yields exceeding 95 per cent, improved purity, and dramatic waste reduction, including elimination of hundreds of thousands of pounds per year of acidic, basic, and solid waste streams. This process underpins the production of **Sertraline** (marketed as Zoloft) ³⁴.

Surfactant-mediated aqueous catalysis further expands the scope of water-based synthesis. Amphiphilic surfactants form micelles that solubilise hydrophobic reactants, enabling reactions such as Suzuki couplings, hydrogenations, and even asymmetric catalysis to proceed efficiently in water. In many cases, yields exceed 90 per cent, with straightforward catalyst recovery and reuse ³⁵.

4.5 Solvent Recycling and Closed-Loop Systems

Even when green solvents are employed, waste streams can accumulate without proper recovery infrastructure. Modern pharmaceutical facilities, therefore, rely on closed-loop solvent management strategies. Fractional distillation routinely recovers more than 90 per cent of volatile solvents, while membrane technologies such as nanofiltration and reverse osmosis reclaim solvents from dilute aqueous streams. Zeolite-based adsorption captures volatile organics for thermal regeneration, and catalytic supercritical water oxidation degrades dissolved organics, allowing water reuse. When integrated effectively, these approaches can reduce E-factors by 50-70 per cent, substantially improving the sustainability of both conventional and advanced syntheses ^{29,30}.

5. Mechanochemistry: Solvent-Free Synthesis Renaissance

5.1 Conceptual Foundation

Mechanochemistry relies on mechanical force rather than heat or solvents to drive chemical transformations. In ball milling, repeated collisions between milling media and reactants generate localised zones of extreme pressure and transient temperature spikes, while the bulk system remains near ambient conditions. These conditions promote radical formation, defect-rich or amorphous phases, and reaction pathways that are inaccessible in solution due to solvent caging effects ³⁶.

5.2 Pharmaceutical Intermediate Synthesis

Solvent-free mechanochemical routes have been demonstrated for several pharmaceuticals. Gram-scale syntheses of nitrofurantoin and dantrolene reported by **Francesco Colacino** and coworkers proceed rapidly under ball milling without solvents, bases, or auxiliary reagents. Reactions are completed within minutes, deliver yields above 95 per cent, and require no chromatographic purification. Compared with conventional routes, cost reductions of 50 to 80 per cent have been estimated, alongside major safety improvements due to the elimination of hazardous acidic work. Significantly, these methods have been scaled to multi-kilogram production using continuous stirred-mill reactors ^{37,38}.

Mechanochemistry has also enabled otherwise difficult selectivity control. For example, synthesis of 1,2-diketoinolizine derivatives via mechanochemical coupling achieves regioselectivities above 95 per cent, outperforming transition-metal-catalysed solution routes while avoiding metal waste entirely ^{36,38}.

5.3 Scale-Up and Catalysis

Industrial-scale mechanochemistry requires continuous or semi-continuous milling rather than small-batch ball milling. Recent advances include large-volume stirred-mill reactors suitable for GMP operations, media-milling equipment with tight particle-size control, and real-time monitoring of force and temperature to provide process feedback comparable to that of conventional reactors. Beyond stoichiometric reactions, mechanochemical catalysis is gaining momentum. Metal-catalysed couplings, enzyme-assisted milling in minimal water, and grinding-induced activation of otherwise inert substrates demonstrate the versatility of this approach ^{36,39}.

5.4 Advantages, Limitations, and Outlook

Mechanochemistry offers clear advantages, including complete solvent elimination, lower energy consumption for many reactions, unique reactivity and selectivity, reduced auxiliary chemicals, and inherently safer operating conditions. However, challenges remain. Mechanistic understanding is less developed than in solution chemistry; scalability requires specialised equipment; reproducibility can be sensitive to physical parameters; and not all

functional groups tolerate mechanical stress. At present, mechanochemistry is best suited to robust, relatively simple transformations³⁹.

Ongoing integration with continuous processing and in situ monitoring is rapidly addressing these limitations. Together, these developments position mechanochemistry as a mature and practical platform for sustainable pharmaceutical synthesis in the coming decade³⁹.

6. Photoredox and Electrochemistry: Light and Electricity as Green Reagents

6.1 Photoredox Catalysis: Visible-Light Powered Synthesis

Photoredox catalysis uses visible light, most commonly blue LEDs in the 410–470 nm range, to drive chemical reactions through single-electron transfer events. Upon light absorption, photocatalysts such as iridium(III) complexes or organic dyes are promoted from the ground state to an excited state with dramatically altered redox properties. This excited catalyst can participate in reductive quenching, in which it accepts an electron from a sacrificial reductant to form a strongly reducing Ir(II) species, or in oxidative quenching, in which it donates an electron to a substrate to generate a powerful oxidising Ir(IV) intermediate. In both cases, the substrate is converted into a controlled radical intermediate that can undergo selective downstream reactions to form carbon–carbon, carbon–nitrogen, or carbon–oxygen bonds. A key advantage of photoredox catalysis is that these transformations often proceed under redox-neutral conditions, with the catalyst cycling between oxidation states driven solely by light, avoiding the need for stoichiometric oxidants or reductants⁴⁰.

These features have enabled a wide range of pharmaceutical applications. One prominent example is trifluoromethylation, where installation of a CF₃ group can improve lipophilicity and metabolic stability of drug candidates. Photoredox methods allow direct CF₃ transfer to aromatic and heteroaromatic systems that are otherwise difficult to functionalize. Work from the group of David W. C. MacMillan demonstrated high-yield trifluoromethylation of an Alzheimer's disease drug precursor, opening access to previously inaccessible analogues. More broadly, photoredox catalysis enables cross-coupling at unactivated C–H positions by generating radicals through hydrogen atom abstraction, followed by selective radical–radical coupling. This strategy has been applied to complex pharmaceutical scaffolds such as indoles and thiophenes, achieving site selectivity that is difficult to realise with traditional cross-coupling chemistry^{40,41}.

Industrial relevance has also been demonstrated. A research team at Pfizer applied photoredox catalysis to a challenging step in the synthesis of the JAK2 inhibitor LY2784544, achieving good yield and selectivity at room temperature with minimal solvent use. Photoredox methods have further been extended to macrocyclization reactions, where intramolecular radical additions enable closure of peptide macrocycles under mild conditions, maintaining compatibility with multiple sensitive functional groups.

Recent developments increasingly combine photoredox catalysis with other catalytic platforms. Metallaphotoredox systems merge photoredox activation with nickel or palladium catalysis, enabling cross-coupling reactions that neither approach can achieve alone.

Organocatalysis–photoredox hybrids allow asymmetric transformations by combining chiral organocatalysts with light-driven radical generation. Enzymatic–photoredox cascades are also emerging, where engineered enzymes operate alongside photoredox cycles to regenerate cofactors such as NAD^+ , enabling multi-turnover biocatalytic processes ^{9,40}.

6.2 Electrochemistry: Electrons Replacing Stoichiometric Reagents

Electro-organic synthesis uses electrical current as a clean reagent to drive oxidation or reduction reactions, replacing traditional stoichiometric oxidants and reductants that generate large quantities of inorganic waste. In direct electrolysis, the substrate is oxidised or reduced directly at the electrode surface, eliminating the need for additional reagents but sometimes requiring high overpotentials that limit functional group compatibility. Mediated electrolysis addresses this limitation by using an electroactive mediator, such as TEMPO or quinones, to shuttle electrons between the electrode and the substrate. This approach allows finer control of redox potential and broader substrate scope, at the cost of introducing an additional catalytic component that must be regenerated ^{21,26}.

A well-established example is TEMPO-mediated alcohol oxidation, where primary and secondary alcohols are selectively converted to aldehydes or ketones at relatively low applied potentials. Copper–TEMPO cooperative systems further lower overpotential requirements and improve selectivity, making these methods attractive for pharmaceutical and natural product synthesis. More recent advances combine electrochemistry with photoredox catalysis to enable transformations such as selective $\text{C}(\text{sp}^3)\text{--H}$ amidation of complex molecules at significantly lower overpotentials than direct electrolysis alone ⁴².

Electrochemistry is particularly effective for heterocycle synthesis, a central process in medicinal chemistry. Electrochemical cyclisation strategies have been developed for the formation of sulfur, nitrogen, and oxygen heterocycles, including thiadiazoles, indoles, quinolines, and isoquinolines. These reactions often proceed under mild conditions with high atom economy, avoiding harsh reagents and minimising waste ^{21,22}.

Scaling electrochemical reactions from laboratory to production scale presents practical challenges. Electrodes must withstand sustained current without fouling or corrosion, mass transfer must be optimised to avoid diffusion limitations, and electrical safety must be ensured at high current and voltage. Economic considerations such as electricity cost, electrode lifetime, and equipment maintenance also influence feasibility. Despite these challenges, electrochemistry offers intrinsic sustainability advantages, including elimination of stoichiometric reagent waste, tunable redox control, and compatibility with continuous processing. Advances in electroflow reactors, bipolar electrode designs, and durable electrode materials are steadily lowering barriers to industrial adoption ^{21,22}.

7. Renewable Feedstocks and Biomass Valorisation

7.1 Strategic Imperative and Feedstock Landscape

Pharmaceutical synthesis ultimately aims to maximise atom economy while minimising waste, reducing the molecular weight and volume of byproducts relative to the desired product. Beyond improvements at the reaction level, a complementary strategy focuses on the upstream supply chain by replacing fossil-derived petrochemical feedstocks with renewable, biomass-derived intermediates. This transition offers several advantages. Biomass feedstocks are effectively carbon neutral because the carbon incorporated into molecules is originally fixed from atmospheric CO₂ through photosynthesis, and end-of-life degradation simply returns this carbon to the natural cycle. In contrast to fossil fuels, which deplete finite reserves, biomass is regenerative over timescales of roughly five to ten years. In addition, biomass components such as cellulose, hemicellulose, lignin, and proteins are rich in oxygenated functional groups, enabling more selective transformations compared with hydrocarbon feedstocks. A further benefit is valorisation of agricultural residues such as corn stover and sugarcane straw, as well as food processing wastes like citrus peels and whey, which can be repurposed as valuable feedstocks rather than treated as disposal burdens ³¹.

7.2 Platform Molecules from Lignocellulosic Biomass

Lignocellulose, the structural polymer network forming plant cell walls, represents approximately 80 per cent of global dry plant biomass. Controlled deconstruction of lignocellulose yields three major fractions that can be converted into pharmaceutical building blocks. The carbohydrate fraction, comprising cellulose and hemicellulose and accounting for roughly 50 to 70 per cent of biomass by mass, consists primarily of C5 and C6 sugars such as glucose, xylose, arabinose, and mannose. These sugars can be catalytically converted to fructose and sorbitol via isomerisation and reduction, providing precursors for large-volume chemicals such as ethylene and propylene. Dehydration of glucose yields 5-hydroxymethylfurfural, a central platform molecule that can be further converted into levulinic acid, furfural, and other furan derivatives used in pharmaceuticals, agrochemicals, and advanced polymer systems. Commercial production of HMF has already been demonstrated, with companies such as AVA Biochem producing tens of tons annually. Fermentation of mixed C5 and C6 sugars can also produce 2,3-butanediol, an essential intermediate for the synthesis of butadiene and methyl ethyl ketone ⁴³.

The lignin fraction, which accounts for approximately 25 to 35 per cent of biomass mass, is a highly cross-linked aromatic polymer that provides structural rigidity to plants. Selective depolymerisation of lignin can yield phenolic compounds such as guaiacol, syringol, and vanillin derivatives, which serve as valuable aromatic intermediates for pharmaceutical synthesis. Benzoic acid derivatives can also be accessed directly, while more advanced valorisation pathways are exploring the conversion of lignin into carbon-based materials with graphene-like properties. At present, more than 95 per cent of extracted lignin is still burned for energy, but maintaining aromatic functionality during depolymerisation could unlock substantial value for pharmaceutical feedstocks ^{31,43}.

7.3 Case Studies: Renewable Feedstock Pharmaceuticals

A prominent example of renewable feedstock integration is artemisinin, a sesquiterpene lactone used in antimalarial therapy and recommended by the World Health Organisation in combination treatments. Traditional extraction from *Artemisia annua* yields only about 0.01 to 0.1 per cent artemisinin by mass, requiring large cultivation areas and generating significant waste. Sanofi pioneered a fermentative approach using engineered *Saccharomyces cerevisiae*, in which ten enzymes from the plant biosynthetic pathway were introduced into yeast. Fed with glucose derived from biomass fermentation, the engineered yeast produces a dihydroartemisinic precursor that is chemically oxidised to artemisinin. This approach eliminates plant extraction, converts low-cost renewable sugars into a high-value drug, ensures a consistent supply independent of agricultural variability, and reduces production costs by more than 50 per cent compared with traditional methods^{44,45}.

Simvastatin provides another example of renewable integration. The drug is produced via fermentation using *Aspergillus terreus*, followed by semi-synthetic modification to install the side chain. Recent advances have replaced conventional chemical side-chain coupling with biocatalytic steps, in which engineered lipases catalyse selective ester or amide formation on fermentation-derived intermediates. This strategy removes hazardous reagents, avoids stoichiometric protecting groups, and enables a more direct route from renewable feedstocks.

A third illustration is L-DOPA, a key therapeutic for Parkinson's disease. Conventional synthesis relies on metal-catalysed hydroxylation of tyrosine, generating significant metal salt waste. Modern routes employ recombinant tyrosinase enzymes that selectively hydroxylate tyrosine in aqueous media. When coupled with upstream production of L-tyrosine via engineered *E. coli* fermentation from glucose, the process becomes an integrated biocatalytic pathway from renewable biomass to the final drug molecule^{31,46}.

7.4 Challenges and Future Perspectives

Despite clear promise, several challenges limit the widespread adoption of biomass-derived feedstocks in the pharmaceutical industry. Biomass pretreatment remains technically demanding, as separating cellulose and hemicellulose from the lignin matrix often requires harsh thermal or chemical conditions, generating salt waste during neutralization. Selective depolymerisation frequently produces complex product mixtures, making separation and upgrading to pharmaceutically relevant monomers difficult. Enzyme limitations also persist, with many biomass-conversion enzymes showing low activity or limited stability, although directed evolution is steadily improving performance.

Economic considerations are equally important. While biomass is cost-competitive for bulk chemicals, the added process complexity can outweigh savings for speciality pharmaceuticals. Biorefinery infrastructure requires substantial upfront capital investment, and reliance on agricultural commodities introduces exposure to market volatility and regional supply risks. Environmental trade-offs must also be carefully assessed, as biomass cultivation requires land, water, fertilisers, and pesticides, all of which contribute to the overall lifecycle footprint. In

addition, some biomass conversion routes still depend on fossil-derived catalysts or processing chemicals³¹.

Ongoing innovations such as consolidated bioprocessing, advanced metabolic pathway engineering, and in situ product separation are steadily improving conversion efficiency and economics. Together, these advances position renewable feedstocks as increasingly viable contributors to pharmaceutical manufacturing, with meaningful impact expected by around 2030^{31,47}.

8. Green Metrics and Quantitative Assessment

8.1 Atom Economy: Theoretical Efficiency

Atom economy (AE), introduced by Trost and defined as the mass of desired product divided by the sum of reactant masses, provides a dimensionless efficiency measure independent of yield:

$$AE = \frac{MW_{\text{product}}}{\sum MW_{\text{reactants}}} \times 100\%$$

Advantages:

- Calculable from molecular structure; no experimental data required
- Ideal for early-stage synthesis planning
- Clearly indicates transformation efficiency

Limitations:

- Neglects catalyst, solvent, and byproduct masses (only considers stoichiometric reagent). Doesn't account for yield; theoretical AE often unattainable
- Less predictive of actual waste than the E-factor

Pharmaceutical example - Ibuprofen synthesis:

Traditional synthesis: 6-step route employing Friedel-Crafts acylation, reduction, esterification, and hydrolysis with 40–50% AE overall.

Catalytic green synthesis (BHC Company): 3-step catalytic route with ~75% AE; combined yield improvement delivers >85% overall product yield vs. 25–30% traditional route^{47,48}.

8.2 Environmental (E)-Factor: The Gold Standard

The E-factor, introduced by Sheldon, quantifies actual waste generation in manufacturing:

$$E\text{-factor} = \frac{\text{Total waste (kg)}}{\text{Product (kg)}}$$

Where total waste includes all byproducts, unreacted starting material, solvents, salts, and auxiliary chemicals.

Interpretation:

- Bulk chemicals: E-factor 1–5 (1 kg waste per kg product)
- Fine chemicals: E-factor 5–50 (5–50 kg waste per kg product)
- Pharmaceuticals: E-factor 25–100+ (25–100+ kg waste per kg product)

Published pharmaceutical E-factors:

Drug	Synthetic Route	E-Factor	Notes
Ibuprofen	Traditional 6-step	40–60	Multiple byproducts, stoichiometric reagents ⁴⁸
Ibuprofen	Catalytic 3-step (BHC)	~8	77% waste reduction ⁴⁸
Efavirenz (HIV)	Traditional	~30	Protecting group chemistry; multiple byproducts ⁴⁹
Efavirenz	Optimized route	~3	90% waste reduction via direct alkynylation ⁴⁹
Sitagliptin	Chemical transamination	~50	Stoichiometric reagents ^{11,15}
Sitagliptin	Enzymatic transamination (Merck-Codexis)	~5.8–8.0	19% waste reduction; biocatalytic selectivity ^{11,15}
Atorvastatin side-chain	Traditional chemistry	~40–60	Multiple protection/deprotection steps ^{50,51}
Atorvastatin side-chain	Enzymatic synthesis	~12–15	Direct side-chain construction ^{50,51}

Calculation complexity:

E-factor calculation requires clarity on system boundaries:

- All solvents included: Assumes solvent not recycled; E-factor 100–200 common
- Solvents recycled: Only net solvent loss counted; E-factor 10–50
- Excluding water: Aqueous processes generate voluminous water; calculations often exclude water to focus on organic waste

Modern practice employs net E-factor (accounting for actual recycled materials) and complete E-factor (all inputs, including water). Comparison requires specification of the calculation methodology. A further refinement, the improved innovation Green Aspiration Level (iGAL 2.0) metric, extends E-factor and PMI by normalising waste against a process's molecular complexity and by incorporating yield and convergence as explicit sustainability indicators, enabling a relative process greenness (RPG) score that lets scientists benchmark new routes against industry-wide baselines and track progress toward United Nations Sustainable Development Goal 12 on responsible production.⁵²

8.3 Process Mass Intensity (PMI)

PMI extends E-factor by incorporating all process inputs (including catalysts, auxiliaries, process aids):

$$PMI = \frac{\text{Total input mass (kg)}}{\text{Product mass (kg)}} \times 100\%$$

PMI is typically 100–400% for pharmaceutical synthesis (1–4 kg input per 1 kg product), compared to an E-factor of 25–100 (reflecting that 25–100% of inputs become byproduct waste; the remainder partitions to product or recyclable solvents).

Advantages:

- More comprehensive than E-factor; it considers process efficiency holistically
- Readily translated to manufacturing cost and environmental footprint
- Preferred by GCIPR for process optimisation

Limitations:

- More complex calculations require detailed input accounting
- Less standardised across the industry

8.4 Life Cycle Assessment (LCA): Cradle-to-Grave Evaluation

Metrics such as the E-factor and process mass intensity are valuable for evaluating inputs and outputs within a manufacturing plant. Still, they do not capture the full environmental footprint of a pharmaceutical product. These metrics exclude impacts associated with feedstock extraction and purification, including energy, water, and land use, as well as upstream chemical production such as solvent synthesis and catalyst manufacturing. Transportation, packaging, and end-of-life disposal or environmental degradation of the product are also outside their scope. Life cycle assessment addresses these gaps by quantifying ecological burden across the entire product lifecycle, from raw material sourcing to disposal. LCA outcomes are commonly reported as global warming potential expressed in kilograms of CO₂ equivalent, along with acidification potential, eutrophication potential, and water consumption. A representative example is sitagliptin, for which enzymatic synthesis shows approximately 30 per cent lower global warming potential than the conventional chemical route, even after accounting for enzyme production. This improvement is primarily driven by the energy efficiency of recombinant yeast fermentation used for enzyme production, substantial reductions in waste generation, and higher overall yields that reduce feedstock consumption per unit of drug substance^{12,51}.

A recent critical review of LCA practice across the pharmaceutical sector notes that despite its analytical rigour, methodological inconsistency remains a major barrier to adoption: system boundaries, functional units, and impact assessment methods vary widely between studies, complicating cross-company and cross-product comparison, and highlighting the need for

sector-specific standardisation of LCA protocols alongside the harmonisation already under way for E-factor and PMI reporting.⁵³

9. Regulatory Framework and Industry Standards

9.1 FDA Guidance and QbD Alignment

The Quality by Design framework, as promoted by the U.S. Food and Drug Administration through ICH-aligned Q8 to Q12 guidances, indirectly encourages the adoption of green chemistry principles. The emphasis on deep process understanding requires detailed characterisation of process parameters, operating ranges, and control strategies, which naturally favours simpler and more efficient processes. Robustness is another core element of QbD, and greener processes often demonstrate improved control characteristics, with waste reduction closely linked to lower process variability. The framework also supports continuous improvement, allowing post-approval manufacturing changes that can incorporate greener process enhancements. Finally, the concept of a multidimensional design space promotes systematic exploration of operating conditions, frequently revealing parameter combinations that are both efficient and environmentally favourable. Although there is no explicit regulatory mandate requiring green chemistry, the overall structure of the QbD framework tends to reward its implementation through streamlined CMC documentation and, in many cases, faster regulatory review.⁵⁴

9.2 European Medicines Agency Environmental Risk Assessment

The revised environmental risk assessment guideline issued by the European Medicines Agency in September 2024 establishes formal requirements for evaluating the ecological impact of marketed medicinal products. The assessment focuses on the persistence of the drug or its metabolites in the environment, the potential for bioaccumulation in living organisms, and the toxicity toward aquatic and terrestrial species. Although the ERA primarily addresses the properties of the drug molecule rather than the manufacturing process, it creates indirect incentives for greener production. Cleaner processes tend to generate fewer impurities, which, in turn, lowers environmental risk profiles. In addition, published evidence of process greenness can influence regulatory perception, and visible commitments to sustainability often improve public and stakeholder acceptance of pharmaceutical products⁴⁷.

9.3 ICH Q11 and Comparability Assessments

ICH Q11, adopted by both the FDA and EMA, imposes stringent requirements for demonstrating comparability following post-approval process changes. These requirements effectively discourage major modifications after approval and create a strong incentive to optimise manufacturing processes early in development. Because optimisation efforts typically focus on efficiency, yield, and control, they frequently lead to greener process designs when sustainability considerations are incorporated from the outset^{6,55}.

9.4 Presidential Green Chemistry Challenge Awards

The annual Presidential Green Chemistry Challenge Awards, administered by the U.S. Environmental Protection Agency since 1995, provide formal recognition and substantial reputational value to companies that successfully implement green technologies. Award recipients gain competitive and marketing advantages, as well as increased regulatory visibility. Notable examples include the Merck–Codexis collaboration, recognised in 2010 for the enzymatic synthesis of sitagliptin, and the 2024 award to Boehringer Ingelheim and Pharma Block for flow-based intermediate manufacturing. Such recognition signals regulatory engagement and innovation leadership, often facilitating partnerships and smoother regulatory interactions^{15,56}.

10. Challenges, Emerging Technologies, and Future Outlook

10.1 Persistent Technical Challenges

Despite rapid progress, several technical challenges continue to limit the full-scale adoption of green and advanced pharmaceutical manufacturing technologies. One of the most significant bottlenecks is the timeline for enzyme discovery and optimisation. Biocatalytic process development typically requires 18–36 months to identify suitable enzymes, conduct directed evolution, and ensure manufacturability at the production scale. Although these timelines are gradually shortening, they often remain misaligned with the urgent demands of time-sensitive programs such as early-stage oncology development or rapid pandemic responses. The integration of high-throughput screening with machine learning is helping to address this issue, with recent ML models demonstrating the ability to predict enzyme activity from sequence data with approximately 80% accuracy, thereby reducing experimental cycles and development time^{10,57}.

Another persistent challenge relates to the economics of scaling green solvent systems. Technologies based on supercritical CO₂ and ionic liquids offer clear environmental advantages, but they require substantial capital investment in specialised equipment, often ranging from 1 to 10 million USD for pharmaceutical-scale reactors. For generic manufacturers operating on narrow profit margins, such investments are difficult to justify without guaranteed production volumes. As a result, shared infrastructure models are emerging in which contract manufacturing organisations provide access to scCO₂ and ionic liquid processing capabilities, lowering the financial barrier to entry³⁰.

Durability issues also affect photoredox and electrochemical platforms. Photoredox catalysts, including iridium(III) complexes and organic photocatalysts, can undergo photodegradation over prolonged operation, increasing the need for catalyst recovery and replacement²³. Similarly, electrodes made of graphite or platinum may suffer from fouling or corrosion during extended use. Ongoing research into alternative materials, such as carbon nanotubes, dimensionally stable anodes, and earth-abundant metal catalysts like nickel-copper, is improving operational stability while simultaneously reducing costs^{21,22}.

Scale-up variability remains a universal challenge across advanced synthesis platforms. Processes that perform well at laboratory scale often exhibit narrower operating windows during scale-up due to limitations in heat and mass transfer, mixing inhomogeneity and dead zones in large vessels, broadening of residence time distributions, and compatibility issues between process streams and construction materials. While rigorous scale-up strategies such as computational fluid dynamics simulations, pilot plant studies, and design-of-experiments approaches help mitigate these risks, they also increase development costs and extend timelines²³.

10.2 Emerging Technologies and Convergence

A new generation of convergent technologies is beginning to reshape pharmaceutical process development. Digital twins and AI-driven optimisation are among the most impactful. These computational replicas of real manufacturing processes, validated using experimental data, enable virtual experimentation and optimisation. By reducing the number of required physical scale-up experiments from hundreds to only a few dozen, digital twins significantly accelerate development while lowering material consumption and waste. When combined with machine learning models trained on large datasets of pharmaceutical synthesis data, AI systems can predict optimal reaction conditions for new transformations with accuracies of 70–80%^{23,57}.

Hybrid reactor systems that combine electrochemical and photochemical transformations in continuous flow are also gaining attention. Electroflow and photoflow integration enables multi-step synthesis within a single platform, where electrochemistry supplies electrons and photoredox catalysis generates reactive radical intermediates. For example, tandem flow systems coupling electrochemical alcohol oxidation with photoredox C–H amidation can access key amine intermediates in two steps rather than the four required in conventional batch routes, improving efficiency and reducing waste N1^{21,42}.

At a more exploratory level, artificial photosynthesis and solar-driven pharmaceutical manufacturing represent long-term, high-risk but high-reward research directions. Current laboratory demonstrations operate at milligram scales and rely on semiconductor photocatalysts to directly harness sunlight for chemical synthesis. The long-term vision is a pharmaceutical manufacturing paradigm powered entirely by renewable solar energy, using CO₂ and water as primary inputs. While scalability to industrial production remains highly speculative, this concept represents a potential moonshot for sustainable manufacturing in the mid-21st century^{42,44}.

Advances in enzyme engineering driven by machine learning are also transforming biocatalysis. Protein language models trained on millions of natural enzyme sequences can now predict properties such as activity, substrate specificity, and thermostability directly from sequence data. When integrated with directed evolution strategies, these tools have the potential to reduce enzyme development timelines from approximately 18 months to as little as 6 months, greatly accelerating the deployment of biocatalytic processes^{10,57}.

Finally, blockchain-enabled supply chain traceability is emerging as an enabling technology for sustainable pharmaceuticals. Distributed ledger systems enable manufacturers to record the

origins of renewable feedstocks, process greenness metrics, and environmental impact data across complex supply chains. This transparency not only helps prevent greenwashing but also supports regulatory compliance and enables premium pricing for demonstrably sustainable pharmaceutical products⁵⁸.

10.3 Future Outlook: 2025–2035 Projections

In the short term (2025–2027), the pharmaceutical industry is expected to see steady adoption of sustainable manufacturing approaches. Continuous flow manufacturing is projected to expand significantly, reaching around 20–30% of API synthesis, up from the current 5–10%. Enzymatic synthesis is likely to move beyond niche and speciality uses to account for approximately 15–20% of commercial API production. Mechanochemistry is anticipated to transition from a niche concept to a recognised and established platform for suitable substrates, while the use of green solvents such as water, supercritical CO₂, and ionic liquid-based systems is expected to approach nearly one quarter of overall industry usage^{30,39}.

During the medium-term period (2028–2032), the integration of multiple green technologies is expected to become a standard industry expectation rather than an exception. Combined approaches involving biocatalysis, continuous flow processing, and green solvents are likely to define best practice in pharmaceutical manufacturing. Regulatory agencies, particularly in the European Union, are expected to introduce mandates specifying minimum E-factor or process mass intensity targets, with similar frameworks likely to be adopted by the FDA thereafter. At the same time, pharmaceuticals derived from renewable feedstocks are projected to represent about 10–15% of APIs, and advanced tools such as photoredox catalysis and electrochemical methods are expected to enter the mainstream synthesis toolbox, contributing to roughly 5–10% of synthetic routes^{31,40}.

In the long term (2033–2035), net-zero pharmaceutical manufacturing is anticipated to become economically competitive with traditional chemistry-based processes^{31,46}. The widespread use of AI-driven process optimisation is expected to dramatically shorten process development timelines, reducing them from the current 3–5 years to approximately 1–2 years. Closed-loop manufacturing systems that incorporate waste valorisation are likely to become the industry standard, reflecting a mature circular economy approach. Additionally, formal environmental impact assessments, comparable in importance to toxicological evaluations, are expected to become a mandatory component of drug approval processes⁵⁸.

11. Conclusion and Strategic Recommendations

The transformation of pharmaceutical intermediate synthesis through green chemistry represents one of the most consequential industrial transitions underway. The convergence of regulatory incentives (FDA QbD, EMA ERA, ICH Q11), economic imperatives (waste-disposal costs, competitive advantage), and technological maturity (biocatalysis, continuous flow, renewable feedstocks) has transitioned green chemistry from aspiration to requirement.

The quantitative evidence is unambiguous: pharmaceutical intermediates synthesised via integrated green methodologies now routinely achieve:

- 50–90% waste reduction (E-factor improvement from 50–100 to 5–20)
- 2–3-fold yield enhancement through improved selectivity and simplified purification
- Superior stereochemical control (>99:1 enantiomeric/diastereomeric excess via biocatalysis)
- Comparable or superior cost at scale, particularly when the total cost of ownership (including waste disposal, regulatory burden, and reputational value) is calculated

For pharmaceutical companies and contract manufacturers, strategic recommendations include:

1. Systematise green chemistry integration: Establish dedicated teams evaluating green alternatives for each synthesis target; do not relegate to academic research periphery
2. Invest in enabling platforms: Capital allocation toward continuous flow equipment, biocatalytic enzyme discovery, and advanced analytical/monitoring capabilities creates a competitive advantage
3. Engage regulatory agencies early: Pre-submission meetings with FDA/EMA discussing green process designs accelerate approvals and build regulatory goodwill
4. Develop talent and partnerships: Hire computational chemists, bioprocess engineers, and catalysis experts; establish partnerships with specialised CROs (contract research organisations) for biocatalysis, continuous flow
5. Measure and communicate: Adopt PMI/E-factor as standard manufacturing KPIs; publish environmental impact data; leverage sustainability narratives for market differentiation
6. Plan for regulatory evolution: Anticipate future mandates for minimum environmental performance; process optimisation today de-risks future compliance

The pharmaceutical industry has successfully navigated multiple transformations from fermentation-based to synthetic chemistry; from empirical to molecular targeted therapeutics. The shift to sustainable manufacturing represents the next evolutionary phase. Companies that embrace this transition gain efficiency, regulatory advantage, and alignment with societal expectations for environmental stewardship. Those that delay face escalating waste-disposal costs, regulatory friction, and challenges in attracting talent. The mathematics of green chemistry yielding products of superior quality at lower waste and cost ultimately make the transition inevitable. The question is not whether green chemistry becomes the industry standard, but how quickly each organisation adapts.

References

1. Sheldon RA. The E factor 25 years on: the rise of green chemistry and sustainability. *Green Chemistry*. 2017;19(1):18-43. <https://doi.org/10.1039/C6GC02157C>
2. Jiménez-González C, Constable DJC, Ponder CS. Evaluating the "greenness" of chemical processes and products in the pharmaceutical industry - a green metrics primer. *Chemical Society Reviews*. 2012;41(4):1485-1498. <https://doi.org/10.1039/C1CS15215G>
3. International Council for Harmonisation (ICH). Q8(R2) Pharmaceutical Development. ICH Harmonised Tripartite Guideline; 2009.

4. European Medicines Agency. Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use (Rev. 1). EMA/CHMP/SWP; 2024.
5. ACS Green Chemistry Institute Pharmaceutical Roundtable. Lessons Learned Through Measuring Green Chemistry Performance: The Pharmaceutical Experience. American Chemical Society; 2014.
6. Cue BW, Zhang J. Green process chemistry in the pharmaceutical industry. *Green Chemistry Letters and Reviews*. 2009;2(4):193-211. <https://doi.org/10.1080/17518250903258150>
7. Anastas PT, Warner JC. *Green Chemistry: Theory and Practice*. Oxford University Press; 1998.
8. Devine PN, Howard RM, Kumar R, Thompson MP, Truppo MD, Turner NJ. Extending the application of biocatalysis to meet the challenges of drug development. *Nature Reviews Chemistry*. 2018;2(12):409-421. <https://doi.org/10.1038/s41570-018-0055-1>
9. Wu S, Snajdrova R, Moore JC, Baldenius K, Bornscheuer UT. Biocatalysis: enzymatic synthesis for industrial applications. *Angewandte Chemie International Edition*. 2021;60(1):88-119. <https://doi.org/10.1002/anie.202006648>
10. Arnold FH. Directed evolution: bringing new chemistry to life. *Angewandte Chemie International Edition*. 2018;57(16):4143-4148. <https://doi.org/10.1002/anie.201708408>
11. Savile CK, Janey JM, Mundorff EC, et al. Biocatalytic asymmetric synthesis of chiral amines from ketones applied to sitagliptin manufacture. *Science*. 2010;329(5989):305-309. <https://doi.org/10.1126/science.1188934>
12. Huffman MA, Fryszkowska A, Alvizo O, et al. Design of an in vitro biocatalytic cascade for the manufacture of islatravir. *Science*. 2019;366(6470):1255-1259.
13. Sheldon RA, Woodley JM. Role of biocatalysis in sustainable chemistry. *Chemical Reviews*. 2018;118(2):801-838. <https://doi.org/10.1021/acs.chemrev.7b00203>
14. Baumann M, Baxendale IR. The synthesis of active pharmaceutical ingredients (APIs) using continuous flow chemistry. *Beilstein Journal of Organic Chemistry*. 2015;11:1194-1219. <https://doi.org/10.3762/bjoc.11.134>
15. Porta R, Benaglia M, Puglisi A. Flow chemistry: recent developments in the synthesis of pharmaceutical products. *Organic Process Research & Development*. 2016;20(1):2-25. <https://doi.org/10.1021/acs.oprd.5b00325>
16. Adamo A, Beingessner RL, Behnam M, et al. On-demand continuous-flow production of pharmaceuticals in a compact, reconfigurable system. *Science*. 2016;352(6281):61-67. <https://doi.org/10.1126/science.aaf1337>
17. Cole KP, Groh JM, Johnson MD, et al. Kilogram-scale prexasertib monolactate monohydrate synthesis under continuous-flow cGMP conditions. *Science*. 2017;356(6343):1144-1150. <https://doi.org/10.1126/science.aan0745>
18. U.S. Food and Drug Administration. FDA approves first continuous manufacturing process for a generic drug product. FDA Press Announcements; 2023.
19. James SL, Adams CJ, Bolm C, et al. Mechanochemistry: opportunities for new and cleaner synthesis. *Chemical Society Reviews*. 2012;41(1):413-447. <https://doi.org/10.1039/C1CS15171A>
20. Tan D, Frišćić T. Towards medicinal mechanochemistry: evolution of milling from pharmaceutical solid form screening to the synthesis of active pharmaceutical ingredients

- (APIs). Chemical Communications. 2016;52(50):7760-7781. <https://doi.org/10.1039/C6CC02015A>
21. Cao Q, Howard JL, Crawford DE, James SL, Browne DL. Translating solid-state organic synthesis from a mixer mill to a continuous twin-screw extruder. *Green Chemistry*. 2018;20(19):4443-4447. <https://doi.org/10.1039/C8GC02036A>
 22. Ardila-Fierro KJ, Hernández JG. Sustainability assessment of mechanochemistry by using the twelve principles of green chemistry. *ChemSusChem*. 2021;14(10):2145-2162. <https://doi.org/10.1002/cssc.202100478>
 23. Prier CK, Rankic DA, MacMillan DWC. Visible light photoredox catalysis with transition metal complexes: applications in organic synthesis. *Chemical Reviews*. 2013;113(7):5322-5363. <https://doi.org/10.1021/cr300503r>
 24. Skubi KL, Blum TR, Yoon TP. Dual catalysis strategies in photochemical synthesis. *Chemical Reviews*. 2016;116(17):10035-10074. <https://doi.org/10.1021/acs.chemrev.6b00018>
 25. Yan M, Kawamata Y, Baran PS. Synthetic organic electrochemical methods since 2000: on the verge of a renaissance. *Chemical Reviews*. 2017;117(21):13230-13319. <https://doi.org/10.1021/acs.chemrev.7b00397>
 26. Huang H, Steiniger KA, Lambert TH. Electrophotocatalysis: combining light and electricity to catalyze reactions. *Journal of the American Chemical Society*. 2022;144(28):12567-12583. <https://doi.org/10.1021/jacs.2c01914>
 27. Elsherbini M, Wirth T. Electroorganic synthesis under flow conditions. *Accounts of Chemical Research*. 2019;52(12):3287-3296. <https://doi.org/10.1021/acs.accounts.9b00497>
 28. Isikgor FH, Becer CR. Lignocellulosic biomass: a sustainable platform for the production of bio-based chemicals and polymers. *Polymer Chemistry*. 2015;6(25):4497-4559. <https://doi.org/10.1039/C5PY00263J>
 29. van Putten RJ, van der Waal JC, de Jong E, Rasrendra CB, Heeres HJ, de Vries JG. Hydroxymethylfurfural, a versatile platform chemical made from renewable resources. *Chemical Reviews*. 2013;113(3):1499-1597. <https://doi.org/10.1021/cr300182k>
 30. Paddon CJ, Keasling JD. Semi-synthetic artemisinin: a model for the use of synthetic biology in pharmaceutical development. *Nature Reviews Microbiology*. 2014;12(5):355-367. <https://doi.org/10.1038/nrmicro3240>
 31. Manley JB, Anastas PT, Cue BW. Frontiers in green chemistry: meeting the grand challenges for sustainability in R&D and manufacturing. *Journal of Cleaner Production*. 2008;16(6):743-750. <https://doi.org/10.1016/j.jclepro.2007.02.025>
 32. U.S. Environmental Protection Agency. Presidential Green Chemistry Challenge: 1997 Greener Synthetic Pathways Award - Improved Synthesis of Ibuprofen (BHC/BASF). EPA; 1997.
 33. U.S. Environmental Protection Agency. Presidential Green Chemistry Challenge: 2002 Greener Synthetic Pathways Award - Redesign of the Sertraline Manufacturing Process (Pfizer). EPA; 2002.
 34. U.S. Environmental Protection Agency. Presidential Green Chemistry Challenge: 2006 Greener Reaction Conditions Award - Biocatalytic Route to the Atorvastatin Side Chain (Codexis). EPA; 2006.

35. U.S. Environmental Protection Agency. Presidential Green Chemistry Challenge: 2010 Greener Reaction Conditions Award - Greener Manufacturing of Sitagliptin Enabled by an Evolved Transaminase (Merck & Codexis). EPA; 2010.
36. Ma SK, Gruber J, Davis C, et al. A green-by-design biocatalytic process for atorvastatin intermediate. *Green Chemistry*. 2010;12(1):81-86. <https://doi.org/10.1039/B919115C>
37. Pierce ME, Parsons RL, Radesca LA, et al. Practical asymmetric synthesis of efavirenz (DMP 266), an HIV-1 reverse transcriptase inhibitor. *Organic Process Research & Development*. 1998;2(5):285-290. <https://doi.org/10.1021/op9800353>
38. Capello C, Fischer U, Hungerbühler K. What is a green solvent? A comprehensive framework for the environmental assessment of solvents. *Green Chemistry*. 2007;9(9):927-934. <https://doi.org/10.1039/B617536H>
39. Jessop PG. Searching for green solvents. *Green Chemistry*. 2011;13(6):1391-1398. <https://doi.org/10.1039/C0GC00797H>
40. Hallett JP, Welton T. Room-temperature ionic liquids: solvents for synthesis and catalysis. *Chemical Reviews*. 2011;111(5):3508-3576. <https://doi.org/10.1021/cr1003248>
41. International Council for Harmonisation (ICH). Q11 Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities). ICH Harmonised Tripartite Guideline; 2012.
42. Coley CW, Green WH, Jensen KF. Machine learning in computer-aided synthesis planning. *Accounts of Chemical Research*. 2018;51(5):1281-1289. <https://doi.org/10.1021/acs.accounts.8b00087>
43. McMullen JP, Jensen KF. Integrated microreactors for reaction automation: new approaches to reaction development. *Annual Review of Analytical Chemistry*. 2010;3:19-42. <https://doi.org/10.1146/annurev.anchem.111808.073718>
44. Lipshutz BH, Ghorai S. Data-driven green chemistry: aqueous micellar catalysis. *Green Chemistry*. 2014;16(8):3660-3679. <https://doi.org/10.1039/C4GC00565A>
45. U.S. Environmental Protection Agency. Presidential Green Chemistry Challenge Award Program: Summary of Winners. EPA; updated periodically.
46. Arden NS, Fisher AC, Tyner K, Yu LX, Lee SL, Kopcha M. Industry 4.0 for pharmaceutical manufacturing: preparing for the smart factories of the future. *International Journal of Pharmaceutics*. 2021;602:120554. <https://doi.org/10.1016/j.ijpharm.2021.120554>
47. Zhu Y, et al. An Engineered Imine Reductase for Highly Diastereo- and Enantioselective Synthesis of β -Branched Amines with Contiguous Stereocenters. *Angewandte Chemie International Edition*. 2024;63:e202408686. <https://doi.org/10.1002/anie.202408686>
48. Pfeiffer M, Ribar A, Nidetzky B. A selective and atom-economic rearrangement of uridine by cascade biocatalysis for production of pseudouridine. *Nature Communications*. 2023;14:2261. <https://doi.org/10.1038/s41467-023-37942-7>
49. Falcini C, de Gonzalo G. Deep Eutectic Solvents as Catalysts in the Synthesis of Active Pharmaceutical Ingredients and Precursors. *Catalysts*. 2024;14(2):120. <https://doi.org/10.3390/catal14020120>
50. Nowak PM, Woźniakiewicz M, Nalepa GJ, Grzybowski BA. The Promise and Pitfalls of Artificial Intelligence in the Evaluation of Synthetic "Greenness". *ChemSusChem*. 2025;18(18):e202500809. <https://doi.org/10.1002/cssc.202500809>

51. Yewale A, Yang Y, Nazemifard N, Papageorgiou CD, Rielly CD, Benyahia B. Deep Reinforcement Learning-Based Self-Optimization of Flow Chemistry. ACS Engineering Au. 2025. <https://doi.org/10.1021/acsengineeringau.5c00004>
52. Cantillo D. Synthesis of active pharmaceutical ingredients using electrochemical methods: keys to improve sustainability. Chemical Communications. 2022;58(5):619-628. <https://doi.org/10.1039/d1cc06296d>
53. Roschangar F, Li J, Zhou Y, et al. Improved iGAL 2.0 Metric Empowers Pharmaceutical Scientists to Make Meaningful Contributions to United Nations Sustainable Development Goal 12. ACS Sustainable Chemistry & Engineering. 2022;10(16):5148-5162. <https://doi.org/10.1021/acssuschemeng.1c01940>
54. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Harmonised Guideline Q13: Continuous Manufacturing of Drug Substances and Drug Products. Step 4 version, 2022.
55. Hastings RH, et al. Investigation of Mechanochemical Sonogashira Couplings—From Batch Solution to Continuous Reactive Extrusion through Ball-Milling Optimization. Organic Process Research & Development. 2023;27(9):1667-1676. <https://doi.org/10.1021/acs.oprd.3c00200>
56. Vornholt T, et al. Of Revolutions and Roadblocks: The Emerging Role of Machine Learning in Biocatalysis. ACS Central Science. 2025. <https://doi.org/10.1021/acscentsci.5c00949>
57. Paddon CJ, Westfall PJ, Pitera DJ, et al. High-level semi-synthetic production of the potent antimalarial artemisinin. Nature. 2013;496(7446):528-532. <https://doi.org/10.1038/nature12051>
58. Chen Z, Lian JZ, Zhu H, et al. Application of Life Cycle Assessment in the pharmaceutical industry: A critical review. Journal of Cleaner Production. 2024;459:142550. <https://doi.org/10.1016/j.jclepro.2024.142550>
59. Dey VD, Verma VS, Pandey AP, Gupta N, Chandrakar JC, Yadav PK. Green pharmaceutical manufacturing: A focus on sustainable approaches to drug formulation development, production & case studies. Indian Journal of Pharmaceutical Chemistry and Analytical Technology. 2025:1-20.
60. Verma VS, Sahu M. Synthesis and characterization of novel organometallic complexes for catalytic applications. Journal of Pharmaceutical Research & Integrated Medical Sciences. 2025;4.
61. Verma VS, Choudhary R, Alexander A, Pandey AK, Pandey A, Ajazuddin. Polyethylene carboxylates synthesized via statistical optimization: A biocompatible polymer scaffold for bioactive conjugation. Biotechnology and Applied Biochemistry. 2026.
62. Verma VS, Jain HK, Badwaik HR, Ajazuddin. Statistical optimization of oxidative derivatization of polyethylene glycol to polyethylene carboxylate using custom design approach. International Journal of Health Sciences. 2022;6(S3):7086-7097.